Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerapolturev (PVSRIPO) in Recurrent Glioblastoma
NCT02986178Phase 2Completed
- Sponsor
- Istari Oncology
- Start
- Jun 2017
- Primary completion
- Sep 2022
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lerapolturev in glioblastoma (GBM) (2 arms), sponsored by Istari Oncology. Primary endpoints: Objective Radiographic Response up to 5 years and Duration of Objective Radiographic Response up to 5 years. Started Jun 2017; status: completed.
02
Drugs
lerapolturev
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02986178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02986178.